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ABSTRACT
Two hundred twenty-four patients with leukemia transplanted with an unrelated donor between 1991 and
2003 at the Karolinska University Hospital were analyzed according to association between graft failure and
ABO, RhD, MNSs, and Kidd blood group antigen compatibility. Median age was 29 years (range: 0-55).
Conditioning consisted of total-body irridiation or busulfan-based myeloablative conditioning. A bone marrow
graft was given to 152 patients, and 72 patients received peripheral blood stem cells. Most patients received
graft-versus-host disease prophylaxis with cyclosporine and MTX. Graft failure (GF) was seen in 6 (2.7%)
patients. In the multivariate analysis major ABO mismatch (odds ratio [OR] 14.9, 95% confidence interval [CI]
2.01-110, P  .008) and HLA-allele mismatch (6.42, 1.19-34.8, P  .03) was significantly associated to GF. In
patients with and without major ABOmismatch the incidence of GF was 7.5% and 0.6% (P .02), respectively.
Using an ABO major mismatched graft increases the risk for GF after unrelated donor hematopoietic stem cell
transplantation.
© 2007 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
s a curative treatment for patients with various he-
atologic malignancies, bone marrow failure syn-
rome, and some inherited metabolic disorders [1-4].
uccessful treatment is mainly hindered by relapse,
nfections, graft-versus-host disease (GVHD), and re-
ection of the graft [5,6]. Donor T cells in the graft
ncourage engraftment, whereas remaining recipi-
nt T cells increase the risk for rejection. Known
isk factors for rejection/graft failure are HLA-
ismatched graft, T cell depletion of the graft, and
educed intensity conditioning [7-9]. When using al-
ernative donors, the risk for graft failure is increased
ompared to when using HLA-identical sibling do-
ors [10,11]. For this reason, many transplant centers
reat the recipients of unrelated donor stem cells with
nti-T cell antibodies (ATG) before infusion of the craft [12,13]. This strategy intends to deplete in vivo
cells in patients. In the past, studies have not con-
idered the incompatibility in the ABO blood group
etween donor and recipient an important factor for
utcome after HSCT [14]. More recent studies, how-
ver, conclude that ABO differences can play a role in
raft rejection and overall survival (OS) [15,16]. Some
tudies suggest that ABO incompatible HSCT is as-
ociated with reduced relapse rates and improved
verall survival in patients with acute leukemia [17].
ntil now, in most centers ABO incompatibility be-
ween donor and recipient was not considered when
electing the optimal donor. In addition, studies have
ot extensively examined the differences in other
lood group systems between donor and recipient and
he relevance of the outcome after HSCT. The Rh
ntigen is assumed to be expressed only on red blood
ells, but other blood group systems such as MNS and
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M. Remberger et al.676uffy are coexpressed on organs and tissue. This
tudy isolates factors associated with rejection/graft
ailure in conventional full-dose conditioned recipi-
nts of HLA-matched unrelated donor stem cells.
ATIENTS AND METHODS
atients
This study includes 224 patients with leukemia
ho received transplants from unrelated donors be-
ween 1991 and 2003 at the Karolinska University
ospital. There were 120 males and 104 females, with
median age of 29 years (1-55). The diagnoses were
cute leukemia (139), chronic leukemia (71), and my-
lodysplastic syndrome (14) (Table 1). At the time of
he transplant, 107 (48%) patients were in ﬁrst com-
lete remission (CR1) or chronic phase.
LA Typing
Before 1997, HLA class I typing was serologic.
ince 1997, we have used PCR-SSP low-resolution
yping for class I. Since July 1992, we have used the
CR methods that use sequence-speciﬁc primer pairs
18]. All patients have recently been retrospectively
etyped using PCR-SSP high-resolution typing for
oth HLA class I and II antigens [19].
able 1. Characteristics of Patients and Donors
n  224
iagnosis
Acute leukemia 139
Chronic leukemia 71
Myelodysplastic syndrome 14
isease stage (early/late)* 107/117
ex (male/female) 120/104
ge 29 (<1-55)
ucleated cell-dose (108/kg) 3.5 (0.2-63.8)
D34 cell dose (106/kg) 5.9 (0.4-56.4)
onor sex (male/female) 136/86
onor age 36 (19-56)
onor
HLA-A, -B, -DR match 200
Allele mismatch 24
onditioning
TBI 10 Gy  Cy 119
Fractionated TBI  Cy 48
Busulfan  Cy 57
TG (Thymo/ATG-F/OKT-3) 161/18/45
VHD prophylaxis
CsAMTX 210
CsAPred or MMF 14
C source (BM/PBSC) 152/72
raft failure 6 (2.7%)
BI indicates total body irradiation; Cy, cyclophosphamide; ATG,
antithymocyte globuline; GVHD, graft-versus-host disease;
CsA, cyclosporine; MTX, methotrexate; Pred, prednisolone;
MMF, mycofenolate mofetil; SC, stem cell; BM, bone marrow;
PBSC, peripheral blood stem cells.tEarly: CR1 or CP1, late; all other.lood Group Serology
ABO and RhD blood typing was done according
o routine methods, both in the solid-phase technique
nd manual tube methods. In the latter case, aggluti-
ation was read microscopically. Rh, MNSs, and Kidd
henotypes were performed in tubes according to the
anufacturer’s instruction either by direct agglutina-
ion or by indirect antiglobulin test. The phenotyping
ncluded Rh, MNS, and Kidd on both the donor and
ecipient. Titration of ABO antibodies in the patient
ample against donor erythrocytes, or if donor eryth-
ocytes were not available, test erythrocytes, was done
ith the standard tube technique.
tem Cell Source
A bone marrow graft was given to 152 patients,
nd 72 patients received stem cells from peripheral
lood after the donor had been mobilized with gran-
locyte colony-stimulating factor (G-CSF) [20]. Red
lood cells (RBCs) were depleted when patients re-
eived ABO major incompatible bone marrow and
xhibited high titer anti-A and/or anti-B. Nucleated
ell dose was determined after RBC depletion.
onors
Median age of the donors (136 males and 86 fe-
ales) was 36 years (19-56). Two hundred patients
nd donor pairs were HLA-A, -B, and -DR identical,
nd 24 patients had an allele-level mismatched donor
2 HLA-A, 9-B, and 13-DR).
onditioning
Conditioning consisted of 120 mg/kg cyclophos-
hamide in combination with 10 Gy single-dose total-
ody irradiation (TBI) (n 119), 4 3 Gy fractionated
BI (n  48), or 16 mg/kg busulfan (Bu) (n  57) [21].
ll patients received antithymocyte globulin (ATG;
hymoglobulin, Genzyme, MA; or ATG-Fresenius,
resenius, Gräfelﬁng, Germany) or OKT-3 for 2-5 days
uring conditioning [12]. One hundred sixty-one pa-
ients received thymoglobulin (2 mg/kg/day), 18 patients
eceived ATG-Fresenius (5 mg/kg/day), and 45 patients
eceived OKT-3 (5 mg/day).
VHD Prophylaxis
As prophylaxis against GVHD, most patients re-
eived cyclosporine (CsA) combined with methotrex-
te (MTX) [22]. Because of anticipated liver toxicity,
TX was replaced by prednisolone in 11 patients.
sA combined with mycophenolate mofetil (MMF)
as given to 3 patients [9].
upportive Care
As a prophylactic gut decontamination, the pa-
ients received ciproﬂoxacin 500 mg twice daily in
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Blood Group Mismatch and HSCT 677ombination with oral amphotericin-B. G-CSF was
iven as prophylaxis to 157 (70%) patients after HSCT
ntil neutrophil engraftment (0.5  109/L) [23,24].
efinitions
An ABO blood group incompatibility occurred if
he recipients and the donors’ blood groups were not
dentical. A minor mismatch occurred when the graft
ontained anti-A and/or anti-B antibodies against
BO blood group antigens on the recipient erythro-
ytes. A major mismatch occurred when the patient
ad anti-A and/or anti-B antibodies against ABO
lood group antigens on the donor erythrocytes. Bi-
irectional mismatch was deﬁned as when both a mi-
or and major mismatch occurred, such as A to B or B
o A.
himerism Analysis
For chimerism analysis, peripheral blood (PB)
amples were collected from the donor and recipient
efore transplant and from the recipient on days 14,
21, 28, and usually every other week up to 3
onths and monthly thereafter [25]. DNA from do-
or and recipient pretransplantation samples was ex-
racted using standard protocols (Qiagen, Hilden,
ermany). To evaluate lineage speciﬁc chimerism,
D3-, CD19-, and CD33-positive cells were selected
rom PB using immunomagnetic beads (Dynal, Oslo,
orway).
The methodology and sensitivity of chimerism
nalysis in the various cell lineages has been described
lsewhere [25]. Brieﬂy, pretransplant recipient and
onor DNA samples were ampliﬁed with 5 different
inisatellite primer pairs to obtain at least 1 informa-
ive locus. PCR analysis, using the chosen primer pair,
as done on sequential patient samples. PCR ampli-
ed products were separated, using a ready-to-use
olyacrylamide gel electrophoresis (PAGE) system
Pharmacia Biotech, Uppsala, Sweden), by 12.5%
ondenaturing PAGE. PCR ampliﬁed band patterns
ere analyzed in visible light after a 90-minute auto-
ated silver staining procedure (Pharmacia Biotech,
ppsala, Sweden). We used a semiquantitative esti-
ation of mixed chimerism that compared recipient-
and intensity and donor-band intensity to a serial
0-step dilution assay by mixing patient and donor
NA.
ngraftment
Marrow engraftment was monitored by daily
lood counts. When appropriate, marrow aspirate cel-
ularity and chimerism was analyzed. Engraftment was
eﬁned as the ﬁrst of 2 consecutive days when ANC
as 0.5  109/L. Graft failure was deﬁned as failure
o produce a persistent donor cell engraftment mea-
ured by chimerism analysis. Primary GF or rejectionas deﬁned as marrow hypoplasia (10% cellularity
n marrow) with a peripheral PMN less than 0.5 
09/L persisting beyond day 21 post-HSCT as con-
rmed by chimerism analysis. Patients were consid-
able 2. Results from the Univariate Analysis of Factors Associated
ith Graft Failure after HSCT with Matched Unrelated Donors
Factor OR CI P
BO match
Identical 1.0
Mismatch 3.38 0.38-29.8 .27
Minor mismatch * * .036
Major mismatch 12.2 1.43-104 .021
Bidirectional MM 6.96 1.28-37.7 .024
hD match
Identical 1.0
Mismatch 1.64 0.29-9.29 .58
NSs match
Identical 1.0
Mismatch 0.55 0.11-2.80 .47
idd match
Identical 1.0
Mismatch 0.62 0.11-3.51 .59
ex
Male 1.0
Female 2.36 0.42-13.3 .33
ge
>10 years 1.0
<10 years 2.36 0.57-16.6 .19
isease stage
CR1/CP1 1.0
Later 4.61 0.54-39.3 .16
C-dose
Continuous 0.98 0.86-1.11 .72
D34 cell dose
Continuous 0.94 0.79-1.13 .51
onor sex
Male 1.0
Female 0.31 0.03-2.72 .29
onor age
Continuous 0.94 0.83-1.05 .25
LA-A, -B, -DR match
Match 1.0
Allele mismatch 4.30 0.79-23.3 .09
LA-C
Match 1.0
Mismatch 3.06 0.62-15.2 .17
LA-C, -DP, -DQ
Match 1.0
No of mismatches 2.01 0.87-4.67 .10
onditioning
Busulfan 1.0
TBI 0.67 0.12-3.82 .65
TG type
All others 1.0
Thymoglobulin 1.99 0.22-17.6 .53
tem cell source
Bone marrow 1.0
Peripheral blood 1.06 0.19-5.94 .95
M indicates mismatch; TBI, total-body irradiation; ATG, anti-
thymocyte globulin; G-CSF, granulocyte colony-stimulating
factor.
Indicates that it is not possible to determine, as no patients with
minor mismatch had graft failure.
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M. Remberger et al.678red to have secondary GF if they initially showed
igns of engraftment and later developed marrow hy-
oplasia that required frequent transfusions beyond
ay 60 and showed no signs of donor cells according
o chimerism analysis.
tatistics
For assessment of factors predicting GF, a meth-
dology was used in a competing risks setting, death
ithin 180 days after HSCT without GF being treated
s a competing event. Univariate and multivariate
nalyses were then performed using Gray’s test and
he proportional subdistribution hazard regression
odel of Fine and Gray. A stepwise backward proce-
ure was used to construct a set of independent pre-
ictors for the endpoint. All predictors with a P-value
.10 were considered and were sequentially removed
f the P-value in the multiple model was.05. All tests
ere 2 sided. The type I error rate was ﬁxed at .05
or factors potentially associated with time-to-event
utcome. Several potential risk factors were studied
Table 2). This analytic approach is designed to gen-
rate predictive factors for GF after HSCT. The in-
idence of graft failure was estimated using a nonpara-
etric estimator of cumulative incidence curves. All
nalyses were carried out using the cmprsk package
developed by Gray, June 2001) on Splus 2000 soft-
are and Statistica software.
ESULTS
lood Group Antigens
One hundred thirty-ﬁve (60%) patients received
n ABO mismatched graft and 89 received an ABO
igure 1. Cumulative incidence of graft failure (GF) and death wit
ell transplantation (HSCT) from unrelated donors.atched graft. Of the mismatched grafts, 67 (30%) mere major mismatched and 68 (30%) minor mis-
atched. A bidirectional mismatch was found in 16
7%) cases. A blood group antigen RhD mismatch was
ound in 53 (24%) cases, MNSs mismatch in 144
64%), and Kidd (Jka/b) mismatch in 99 (44%) cases.
raft Failure
Graft failure (GF) was seen in 6 (2.7%) patients
ith a median of 64 days (range 23-132) after HSCT
Figure 1). Of these 6 patients, 3 had primary GF or
ejected their grafts and 3 had a secondary GF. In the
nivariate analysis, 4 factors were signiﬁcantly associ-
ted with GF (Table 2). In the multivariate analysis,
ajor ABO mismatch (odds ratio [OR] 14.9, 95%
onﬁdence interval [CI] 2.01-110, P  .008) and
LA-A, -B, or -DR allele level mismatch (6.42, 1.19-
4.8, P  .03) were the only factors signiﬁcantly
ssociated with GF. No correlation between other
lood group antigens (Rh, MNSs, and Kidd) and GF
as found (Table 2). In patients with and without
ajor ABO mismatch, the incidence of GF was 7.5%
5 of 67) and 0.6% (1 of 157) (Figure 2a, P  .02),
espectively. In patients with and without HLA allele-
evel mismatch, the incidence of GF was 8.3% (2 of
4) and 2.0% (4 of 200) (Figure 2b, P  .09), respec-
ively. In patients with both a major ABO mismatched
nd an HLA-allele mismatched donor (n  5), the
ncidence of GF was 20%. None of the 138 patients
ith no risk factors developed GF (Figure 3). Patients
ith GF are displayed in Table 3.
The procedure of removal of RBCs from ABO
ajor mismatched bone marrow (BM) grafts led to a
ecrease in total nucleated cell (NC) count by 20%.
owever, when comparing the NC counts in ABO
F in 224 patients with leukemia who received hematopoietic stemhout Gajor mismatched BM grafts (RBC removal) with all
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Blood Group Mismatch and HSCT 679BO nonmajor mismatched BM grafts (no RBC re-
oval) no statistical difference was seen (2.5 [0.2-17.0]
ersus 2.6 [0.7-13.1], P  .5). Furthermore, there was
o difference in cell counts in grafts with ABO major
ismatched BM grafts with and without GF (2.2 [0.7-
4.0] versus 2.5 [0.2-17.0], P  .8). Among patients
eceiving a peripheral blood stem cell graft, the 2
atients with GF were both HLA-C mismatched (Ta-
le 3), raising the possibility that HLA-C may be
esponsible for these GF. In total, there were 21
LA-C mismatches in the PBSC group, and 2 of
hese suffered a GF (9.5%). However, it is not possible
o statistically determine this in our model as the
igure 2. Cumulative incidence of graft failure (GF) depending on
eukemia who received hematopoietic stem cell transplantation (HSumbers of graft failures were too few. [We found no difference in ABO antibody titers
etween patients with and without GF in major ABO
ismatched transplants. The IgG antibody titers were
6 (8-128) and 32 (1-1000), the IgM titers 8 (1-32) and
2 (1-1000) in patients with and without GF, respec-
ively (ns).
ISCUSSION
Known factors increasing the risk for rejec-
ion/GF include HLA-mismatched graft, T cell-de-
leted graft, and reduced intensity conditioning (RIC)
O compatibility and b) grade of HLA match, in 224 patients with
rom unrelated donors.a) AB7-9]. However, in HLA-matched full-dose conven-
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M. Remberger et al.680ional conditioning and non-T cell depleted HSCT,
he risk for GF is increased when using unrelated
onors compared to HLA-identical sibling transplants
11]. The reason for this may be minor histocompat-
bility antigen differences and other unknown factors.
n this study, we analyzed 224 consecutive patients
ith HLA antigen-matched unrelated donors receiv-
ng an unmanipulated graft and conventional full-dose
onditioning. Historically, the risk for GF in this
opulation is approximately 5%. We found the inci-
ence to be 2.7% in our material. One reason for the
ow incidence may be that we treat all recipients of an
nrelated donor graft with ATG, and that we use
igh-resolution genomic HLA typing [19,21]. When
sing ATG, the recipient’s in vivo T cells are de-
leted, which may reduce the risk for GF.
igure 3. Cumulative incidence of graft failure (GF) depending on
ismatch and HLA allele mismatch) in 224 patients with leukem
nrelated donors.
able 3. Patient Characteristics for Patients with Graft Failure after U
UPN Age Gender Diagnosis
SC dose
108/kg
SC
Source Condit
397 1 M AML PR 14 BM FTBI/C
523 29 F ALL PR 2.1 BM TBI/Cy
620 47 F
AML
CR1 8.4 PBSC TBI/Cy
679 13 F ALL CR2 0.7 BM FTBI/H
850 27 M
AML
CR2 5.8 PBSC Bu/Cy
911 3 F
AML
CR2 2.2 BM Bu/Cy
indicates male; F, female; AML, acute myelogenous leukemia
remission; SC, stem cell; BM, bone marrow; PBSC, peripheral b
phamide; VP, vepecid; Bu, busulfan; CsA, cyclosporine; MTX,Allele level mismatch.In this study, patients with an HLA-A, -B, or -DR
llele-level mismatched donor had an increased risk
or GF. This is not surprising, as even small differ-
nces within the HLA-system may increase the risk
or immunologic reactions such as GVHD and rejec-
ion. In the multivariate analysis, we found no associ-
tion between HLA-C mismatch, or additional mis-
atches within the HLA-DP and -DQ antigens, and
F. However, among patients receiving a PBSC graft
he 2 with GF were both HLA-C mismatched (Table 3),
aising the possibility that HLA-C may be responsible
or these GF [8].
Graft cell dose has previously been shown to be
ssociated to GF [26]. In the present study we were
ot able to verify that ﬁnding.
We studied the effect of differences in various
r of risk factors (RF) found in the multivariate analysis (ABO major
received hematopoietic stem cell transplantation (HSCT) from
d Donor Stem Cell Ttransplantation
Immune
Suppression
Donor
Blgr
Recip
blgr HLA Mismatch GF Day
CsAMTX A O DP 90 (gf)
CsAMTX B O 90 (gf)
CsAMTX B A CDP 38 (gf)
CsAMTX A O DR*CDPDQ 23 (rej)
CsAMTX O O B*CDP 132 (gf)
CsAMTX A B DP 27 (rej)
acute lymphoid leukemia; PR, partial remission; CR, complete
em cells; FTBI, fractionated total-body irradiation; Cy, cyclophos-
rexate; blgr, bloodgroup; rej, rejection; GF, graft failure.numbe
ia whonrelate
ioning
y/VP
oloxan
; ALL,
lood st
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Blood Group Mismatch and HSCT 681lood group antigens between the recipient and do-
or. We found that a major ABO mismatched graft
as a factor associated to an increased risk for GF (OR
4.9, 95% CI 2.01-110, P  .008). In the univariate
nalysis, a bidirectional ABO mismatch also was asso-
iated with GF, but in the multivariate analysis major
BO mismatch was the strongest factor. A major
ismatch implies that the patient had isohemagglu-
inins against ABO blood group antigens on the
onor erythrocytes. Among the other blood group
ntigens studied, no antibodies occur naturally; they
ccur only after immunization after transfusions or
regnancies.
There are many reports concerning the effect of
BO incompatibility on results after HSCT. These
eports present conﬂicting results regarding the role
f ABO match between patient and donor in HSCT.
owever, there are now some reports showing a de-
ayed recovery of neutrophils and graft rejection in
ajor ABO mismatched transplants [27-29]. The ex-
lanation for the ﬁnding of delayed neutrophil en-
raftment and increased graft failure may be the pres-
nce of antidonor A/B or neutrophil antibodies [30]. It
eems likely that high pretransplantation levels of an-
idonor isoagglutinins and/or residual host B and
lasma cells escaping the conditioning regimen may
e responsible for these effects. Antidonor A/B anti-
odies may bind to A/B antigens absorbed on the
urface of neutrophils or their precursors in the bone
arrow, a condition that could lead to elimination
r suppression. At any rate, this process seems slow
nd time consuming, because graft failure was not
cute in any case and appeared between 23 and 90
ays after transplantation (Table 3). This is in con-
rast to T cell-mediated rejection, which can cause
ither allogeneic resistance with no engraftment of
onor cells or an acute rejection occurring within
ays. However, in this material no correlation be-
ween titers of antidonor A/B antibodies and GF was
ound.
ONCLUSION
This study shows for the ﬁrst time that is an
ncreased risk for graft failure may exist when using a
ajor ABO mismatched unrelated donor. With in-
reasing availability of HLA matched unrelated do-
ors, the ABO compatibility between donor and re-
ipient may be considered when selecting the donor.
specially when using HLA allele mismatched do-
ors, a major ABO mismatch should be avoided if
ossible.
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